Financial Data and Key Metrics Changes - As of September 30, 2025, the company's cash and cash equivalents were $23.9 million, sufficient to fund planned operating expenses into early Q2 2026 [20] - Revenue for Q3 2025 was $615,000, a decrease from $1.7 million in the same period last year, reflecting the timing of partner-funded program activities [20] - Research and development expenses decreased to $10.8 million from $13 million year-over-year, primarily due to cost-reduction initiatives [21] - Selling, general, and administrative expenses were reduced to $5.2 million from $7.7 million in the previous year [21] - The net loss for Q3 2025 was $24.3 million, significantly improved from a loss of $201.5 million in the year-ago period, which included a $181.4 million non-cash goodwill impairment charge [22][23] Business Line Data and Key Metrics Changes - The company signed seven RISE customer agreements in the U.S. and Latin America, representing approximately 5-7 million addressable acres for herbicide-tolerant traits HT1 and HT3, with potential annual royalties exceeding $200 million [6][7] - The RISE traits are on track for initial commercial launch in Latin America in 2027, followed by the U.S. in 2028 and Asia around 2030 [8][11] - The biofragrance program achieved critical milestones with successful pre-commercial pilot runs, positioning the company to receive initial payments in Q4 2025 [12] Market Data and Key Metrics Changes - The company is expanding its customer base in Latin America and is positioning for entry into the Asian markets, particularly India, which has approximately 120 million acres under rice cultivation [10][35] - The regulatory environment is improving, with positive determinations in Ecuador and ongoing approvals across North and South America, as well as progress in India and parts of Asia [14] Company Strategy and Development Direction - The company is focused on commercialization and production activities, particularly in weed management traits and biofragrance business, to capture near-term revenue opportunities [4][5] - The streamlined strategic focus has led to significant commercialization momentum, validating the decision to prioritize high-value opportunities [4][5] - The company aims to reduce annual net cash usage to approximately $30 million by 2026 through disciplined capital allocation and operational efficiencies [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the gene-editing revolution in agriculture, emphasizing the company's readiness to capitalize on commercialization opportunities [24][25] - The regulatory environment is seen as a catalyst for growth, with expectations for the EU regulatory process to finalize by year-end 2025 [31][33] - The company anticipates initial revenues from biofragrance products in 2026, with a long-term revenue potential in the $20 million-$40 million range [47] Other Important Information - The company has strengthened its board with new appointments to support commercialization efforts [5][6] - The standardized rapid trait development system (RTDS) is recognized as a breakthrough in agricultural innovation, enhancing the company's ability to deliver edited germplasm to customers [11][17] Q&A Session Summary Question: Potential for R&D sharing or bespoke R&D projects in 2026 - Management indicated significant opportunities for expanding R&D collaborations in 2026, driven by regulatory tailwinds and inbound interest for partnerships beyond current focuses [27][28] Question: Timeline for EU regulations finalization - Management believes the final text for EU regulations will be completed by year-end 2025, marking a significant moment for the industry [31][33] Question: Total addressable market for rice in key regions - The company estimates a total addressable market of over 120 million acres in India and 5-7 million acres in Latin America and the U.S. [35][39] Question: Differences between HT traits and pod shatter reduction - Management explained that herbicide-tolerant traits are essential for weed management and have a well-understood business model, making them easier to integrate into breeding programs compared to pod shatter reduction traits [40][41] Question: Revenue expectations for biofragrance products in 2026 - Initial revenues from biofragrance products are expected to be in the single-digit millions, with potential to ramp up significantly in subsequent years [47][55] Question: Update on automation and improvements in the real-time delivery system - Management highlighted improvements in editing frequency and regeneration efficiency, with ongoing automation efforts to enhance operational efficiency [63][64]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was reported at $20.7 million, reflecting a 9% growth year-over-year, driven by stronger adoption and new accounts [4][14] - Gross margin remained stable at 68% for both Q3 2025 and Q3 2024, with gross profit increasing to $14 million from $12.9 million [14] - Net loss decreased to $8.6 million in Q3 2025 from $10.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue from OviTex grew by 6%, while OviTex PRS revenue increased by 12% compared to the prior year [14] - OviTex unit sales grew by 22% in Q3, while PRS unit sales saw a 3% increase [14] Market Data and Key Metrics Changes - International sales grew by 9%, with notable traction in the U.K. and early progress from the OviTex IHR launch in Europe [4] - The company expanded its market presence in the U.S. by adding 835 hospitals to its portfolio [9] Company Strategy and Development Direction - The company is focused on expanding its commercial footprint, improving operational discipline, and strengthening its patient-centric culture [4] - Investments in the sales organization are expected to enhance commercial performance moving forward [5] - The company aims to become a market leader in hernia and plastic reconstructive surgery through enhanced medical education and market access strategies [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 16% revenue growth for the full year 2025 compared to 2024 [16] - For 2026, the company anticipates at least 15% revenue growth from 2025, with a focus on hiring and operational efficiency [17] Other Important Information - The company announced a refinancing and upsizing of its debt facility from $40 million to $60 million, along with a $13 million equity offering, adding approximately $26 million in net cash [18] - The company has surpassed 100,000 implantations of OviTex and OviTex PRS globally, indicating strong market impact [7] Q&A Session Summary Question: Rationale for debt refinancing and equity raise - Management feels comfortable with the cash runway, stating the refinancing was proactive to avoid future amortization issues and to secure additional capital [25] Question: Guidance for 2025 and 2026 growth expectations - The company provided a conservative growth estimate for 2025, factoring in hiring and operational adjustments, with a goal of at least 15% growth for 2026 [26][27] Question: Details on Salesforce hiring - The company aims to increase its Salesforce to over 90 territory managers by Q1 2026, with a focus on hiring high-caliber talent [31][34] Question: Break-even profile - Management continues to target a break-even point in the high $20 million range per quarter, emphasizing operational efficiency [36] Question: Q4 growth expectations - The company expects at least 16% year-over-year growth in Q4, with potential upside from recent hiring and organizational improvements [46]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 47% year over year to $23.5 million, with Irwin Naturals contributing $6.8 million to the revenue increase [3][4] - Gross margin declined to 37.2% from 43.8% year over year, primarily due to lower margins in the MusclePharm business and the addition of Irwin, which has historically lower margins [4][5] - Net income for Q3 2025 was $0.9 million, down from $2.1 million in Q3 2024, attributed to elevated merger-related expenses and lower gross margins [5][6] Business Line Data and Key Metrics Changes - Legacy FitLife revenue for Q3 2025 was $12.9 million, with a 4% increase in wholesale revenue but an 8% decrease in online revenue [6][7] - MusclePharm revenue increased by 55% in Q3 2025, with wholesale revenue up 112% and online revenue down 3% [7][8] - Irwin Naturals generated $6.8 million in revenue during the 53-day period post-acquisition, with 95% from wholesale and 5% from online sales [8][9] Market Data and Key Metrics Changes - Wholesale revenue for the quarter was $13.2 million, a 156% increase compared to Q3 2024, with other brands' wholesale revenue increasing by 30% year over year [4][6] - Online revenue was $10.3 million, accounting for 44% of total revenue, a decrease of 5% compared to Q3 2024 [4][5] - The company noted a decline in Amazon subscriber counts starting in September 2025, indicating a broader consumer weakness [16][17] Company Strategy and Development Direction - The company is focused on optimizing online sales and has ceased wholesale sales to a primary Amazon seller to enhance future online revenue [9][11] - Management anticipates that Irwin's gross margin will improve over time as online sales increase and supply chain efficiencies are realized [11][12] - The company is considering a price increase for MusclePharm products effective January 1, 2026, to mitigate rising whey protein costs [7][15] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns about general consumer weakness and its impact on subscription growth, noting that the decline in subscriber counts was unexpected [16][17] - The company is monitoring the rising costs of whey protein and anticipates further increases, which may pressure margins in the near term [15][18] - Management remains optimistic about future growth opportunities, particularly in online sales and brand optimization [12][14] Other Important Information - The company did not pay down any debt during Q3 2025, focusing cash flow on acquisition-related expenses [13][14] - The effective tax rate was unusually high due to a true-up of the 2024 tax provision, which is not expected to be a recurring issue [6][50] Q&A Session Summary Question: What percentage of the business came from recurring subscriptions? - Management indicated that prior to the Irwin acquisition, 20-25% of online revenue was from subscriptions, but this percentage has decreased post-acquisition due to Irwin's minimal online presence [20][21] Question: How much of MusclePharm's growth was from new versus existing customers? - Management estimated that the growth was primarily from existing customers, with a rough guess of 80% existing and 20% new [24][25] Question: What was the year-over-year performance of Irwin Naturals? - Management acknowledged that Irwin's performance would show a decline year-over-year due to lost sales from Costco but did not provide specific figures [26][28] Question: Have you worked through the stepped-up inventory? - Management confirmed that approximately 40% of the stepped-up inventory has been worked through, with the remaining expected to impact Q4 [33][34] Question: What is the ongoing issue with Dr. Tobias? - Management noted a significant drop in traffic to Dr. Tobias listings on Amazon, attributing it to potential changes in Amazon's algorithm [43][44] Question: How are competitors dealing with rising protein costs? - Management observed that while they have not raised prices, competitors are likely passing on costs, which has allowed the company to gain market share [72][73]

Financial Data and Key Metrics Changes - For Q3 2025, Omeros reported a net loss of $30.9 million, or $0.47 per share, compared to a net loss of $25.4 million, or $0.43 per share in Q2 2025 [4][16] - The adjusted net loss, excluding non-cash charges, was $22.1 million, with an adjusted loss per share of $0.34 [5][16] - Cash burn for the quarter was $22 million, with $36.1 million in cash and investments as of September 30, 2025 [5][17] Business Line Data and Key Metrics Changes - The third-quarter results included $8.8 million in non-cash charges related to embedded derivatives associated with debt [4][16] - Research and development expenses were primarily focused on Zaltenibart and Yartemlya [19] Market Data and Key Metrics Changes - The biologics license application for Yartemlya remains under FDA review, with a PDUFA date of December 26, 2025 [9][10] - The marketing authorization application for Yartemlya in Europe is under review, with an anticipated decision in mid-2026 [10] Company Strategy and Development Direction - Omeros announced a definitive agreement with Novo Nordisk for an asset purchase and license transaction valued at up to $2.1 billion [5][6] - The transaction will provide Omeros with $240 million in upfront cash, which will be used to repay existing debt and fund operations [6][17] - The company is preparing for the commercial launch of Yartemlya, having established a national ICD-10 diagnostic code and an associated CPT procedural code [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the approval decision for Yartemlya and the potential for cash flow positivity in 2027 [26] - Engagement with transplant centers and payers has been positive, driven by the drug's demonstrated benefits [11][12] - The company is focused on advancing its pipeline, including MASP-2 small molecules and oncology programs [41][42] Other Important Information - The company expects overall operating expenses in Q4 2025 to be higher than in Q3, primarily due to increased marketing costs [22] - Income from discontinued operations is expected to be in the $5-$6 million range, excluding non-cash adjustments [24] Q&A Session Summary Question: Post-approval launch timeline for narsoplimab - Management indicated that launch preparations are underway and would move quickly upon approval [25] Question: Details on NTAP for Yartemlya - Management confirmed they expect to receive NTAP, which will help defray costs for hospitals [29][30] Question: Labeling discussions with the FDA - Management stated they do not comment on specific FDA discussions but have provided substantial data for both adult and pediatric patients [31][32] Question: Outlook for operating expenses in 2026 - Management expects expenses to increase, contingent on the closing of the Novo deal and FDA approval [39]

Financial Data and Key Metrics Changes - For Q2 fiscal 2026, consolidated revenue was $9.1 million, a 2% increase from $8.9 million in Q2 fiscal 2025 [5][10] - Consolidated gross profit rose to $2.5 million, an increase of $1.4 million compared to the same period last year, resulting in a gross margin improvement of 16 percentage points [5][9] - Net income for the quarter was $0.8 million, or $0.08 per share, compared to $0.2 million, or $0.02 per share, for the same quarter last year [10][11] Business Line Data and Key Metrics Changes - Raynor segment revenue was $4.4 million with an operating profit of $1.6 million, while Statco revenue was $4.8 million with an operating loss of $0.5 million, although Statco showed an $873,000 improvement in operating income year-over-year [5][12] - Statco experienced a year-over-year gross profit margin improvement of 9 percentage points, primarily due to better contract pricing and production efficiencies [12] Market Data and Key Metrics Changes - The company reported a strong backlog of $48 million, expected to be delivered over the next one to three fiscal years, indicating robust demand in the defense sector [7][14] - The company continues to focus on building a strong recurring revenue customer base, which is critical for future growth [8] Company Strategy and Development Direction - The company aims to secure and maintain enduring partnerships with customers in the defense sector, particularly in naval submarine manufacturing [13][14] - Management emphasized the importance of aggressive cash management and controlling expenses to mitigate risks and enhance customer confidence [6][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growing revenue and increasing profitability in future quarters, despite challenges faced by the Statco subsidiary [14] - The company is actively working with customers to address legacy contracts and pricing issues, aiming for recovery and improved profitability [12][20] Other Important Information - The company is focused on tactical execution and maintaining on-time delivery of quality components, which has led to new quoting opportunities in air defense and submarine defense sectors [6][7] - Management highlighted the importance of customer collaboration to mitigate risks associated with first article activities [20][25] Q&A Session Summary Question: What percentage of your Statco business is still needing to be reworked to become profitable? - Management indicated that while they cannot specify a percentage, they are actively addressing loss reserves and first article activities to improve profitability [19][20] Question: Is the problem with first articles more related to design issues or underbidding? - Management noted that issues vary on a case-by-case basis, emphasizing the complexity of the items being manufactured and the need for better collaboration with customers [23][24] Question: Do you see the shifting of the former Philadelphia Naval shipyard to a submarine manufacturer as an economic opportunity? - Management expressed willingness to explore every opportunity that arises [27][28] Question: Can you walk through how you handle the grants received from the federal government? - Management explained that they segregate liabilities upon receipt of cash and ensure that they get paid for everything built with the new equipment [32][35] Question: What kind of new business have you seen, particularly out of the Raynor operation? - Management confirmed involvement in programs related to Virginia-class and Columbia-class submarines, indicating ongoing opportunities [37][38]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $36.1 million, a 4% increase from $34.6 million in Q3 2024 [22] - Adjusted EBITDA for Q3 was $344,000, with a sequential increase of 88% [28] - Free cash flow for Q3 was $324,000, representing a 260% sequential increase [28] - Net loss for Q3 was $559,000, compared to a net loss of $425,000 in the same period last year [27] Business Line Data and Key Metrics Changes - Carrier services revenue for Q3 was $20.4 million, a decrease from $22.4 million in Q3 2024 [23] - Managed services fees for Q3 were $10.1 million, an increase from $8.5 million in the same period last year [23] - Billable services fees for Q3 were $1.3 million, down from $1.7 million in Q3 2024 [24] - Reselling and other services in Q3 were $4.3 million, an increase from $2 million in the same period last year [24] Market Data and Key Metrics Changes - The company ended Q3 with a federal contract backlog of approximately $269 million, providing solid revenue visibility for the coming year [29] - The recent contract with a major telecommunications carrier is expected to generate $40-$45 million in SaaS revenue over three years, starting in the second half of 2026 [29] Company Strategy and Development Direction - The company is focused on margin-accretive contracts through its FedRAMP-authorized ITMS platform and aims to capture significant opportunities in the government sector [31] - The company is strategically positioning itself for the upcoming CWMS 3.0 contract and has received a six-month extension on its CWMS 2.0 contract [8][9] - The company is also investing in its Device-as-a-Service (DAS) solution and pursuing larger-scale opportunities [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to a growth trajectory and anticipates that delayed opportunities will materialize in the coming year [13] - The company has no immediate material impact from the government shutdown but acknowledges potential slowdowns in activities if it persists [12] - Management remains optimistic about the financial results for Q4 and 2026, expecting continued growth in adjusted EBITDA and free cash flow [28] Other Important Information - The company ended Q3 with $12.1 million in cash, compared to $6.8 million at the end of Q2 [30] - The company is exploring potential acquisition opportunities but is cautious due to high valuations in the market [39] Q&A Session Summary Question: Details on the $40-$45 million contract - The $45 million contract is not included in the $269 million backlog and is expected to be implemented starting in Q3 2026 [35] Question: Exclusivity with the telecommunications carrier - The company does not have exclusivity with the carrier and is hopeful to engage with other major carriers in the future [36] Question: Cash balance and M&A opportunities - The company is maintaining a strong cash position for operations and is quietly looking for acquisition targets, though no material opportunities have been found yet [39] Question: MobileAnchor implementation and its impact - Implementation typically takes about 60 days, and the project is progressing well despite delays due to the government shutdown [52] Question: Opportunities with the Olympics - The company will support CDW in managing devices for the Los Angeles 2028 Olympics, estimating the need for managing between 95,000-135,000 devices [65]

Financial Data and Key Metrics Changes - Net revenue for Q1 2026 was $13.9 million, down from $16.6 million in the prior year, but excluding a one-time rebate benefit from last year, net revenue increased by 5% [17][21] - ADHD portfolio net revenue was $13.2 million compared to $15.3 million in the prior year, but on an equivalent basis, it increased by about 10% [17][21] - Gross margin decreased to 66% from 72% year-over-year, but improved to 65% when excluding the rebate [18][21] - Operating expenses were $10.2 million, down from $11.2 million in the prior year, reflecting cost reduction efforts [19][21] Business Line Data and Key Metrics Changes - The ADHD portfolio showed resilience with a 10% increase in net revenue on an equivalent basis, despite a decrease in total prescriptions [17][21] - The pediatric portfolio revenue dropped to $0.7 million from $1.3 million due to manufacturing delays and a de-emphasis in marketing [18][21] Market Data and Key Metrics Changes - The company is preparing for the launch of Exxua, which is expected to significantly impact the market for major depressive disorder treatments [5][10] - The ADHD market remains highly genericized, but the company believes its unique distribution model will mitigate the impact of generic competition [12][13] Company Strategy and Development Direction - The company is focused on the successful launch of Exxua, with significant preparations underway including KOL engagement and Salesforce training [5][10] - Aytu is maintaining a Salesforce of approximately 40 people, with territory alignments adjusted for optimal market access [8][9] - The company is also working on lifecycle management approaches to extend exclusivity beyond 2030 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ADHD portfolio's resilience despite the threat of generic competition, citing the unique distribution model [12][13] - The company anticipates a strong launch for Exxua, with positive feedback from prescribers and a focus on targeting younger patients dissatisfied with current treatments [27][44] Other Important Information - The FDA's recent communication regarding fluoride-containing drugs is being monitored, but the impact on Aytu's financials is expected to be minimal [15][16] - Cash and cash equivalents were $32.6 million at the end of the quarter, up from $31 million [22] Q&A Session Summary Question: How significant were the territory realignments and what are the plans for incentive compensation post-Exxua launch? - Approximately one-third of the territories were affected, with a focus on enhancing coverage in key areas. A rich incentive compensation plan is being finalized to reward engagement with new prescribers [30][31] Question: What has been done regarding payer engagement pre-launch? - The company is taking a cautious approach to contracting with commercial payers to maintain best pricing on government contracts, with light engagement ongoing [33][35] Question: How much of the target prescriber market has been reached and what feedback has been received? - Feedback from engaged prescribers has been overwhelmingly positive, with a focus on targeting psychiatrists already familiar with Aytu's products [40][41] Question: What is the flexibility of the supply chain to ramp up production if demand exceeds expectations? - The company has sufficient supply to meet initial forecasts and can scale production as needed, with a low cost of goods sold projected [49][51]

Financial Data and Key Metrics Changes - The company generated $617.1 million in revenue for Q3 2025, which is up 0.4% year-over-year and 0.5% sequentially, exceeding previous guidance by $2 million [4][20] - Adjusted gross profit margin remained flat at 38.1%, while adjusted operating margin increased by 50 basis points sequentially to 15.5% [20][22] - Adjusted net income for the quarter was $69.7 million, maintaining an adjusted net profit margin of 11.3% [22] - Free cash flow generated during the quarter was $67.5 million, achieving a free cash flow-to-adjusted net income ratio exceeding 96% [22][23] Business Line Data and Key Metrics Changes - The AI bots and subscription model have nearly doubled their share in the pipeline, indicating strong demand for AI-based solutions [8][9] - The top five clients grew sequentially by 2.1%, which is above the company's average growth [6] - The share of clients identified as Hundred Square potential increased to 56.7%, up from 50% last year [7] Market Data and Key Metrics Changes - The pipeline reached an all-time high of $3.7 billion, representing a 30% year-over-year growth [5] - The AI market is expected to grow to $4.8 trillion by 2033, indicating a significant opportunity for the company [5] Company Strategy and Development Direction - The company is focusing on sustainable growth and delivering exceptional value through innovation, particularly in AI solutions [3][4] - The shift to a subscription revenue model is being embedded with 17 of the top 20 customers, reflecting a strong acceptance of this new approach [9][84] - The company aims to redefine consulting by eliminating traditional barriers and focusing on outcome-driven models [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a strong pipeline and increased client engagement in AI transformation projects [34][41] - The company anticipates better growth rates in 2026 based on the current pipeline and client conversations [41][75] - Management acknowledged the challenges posed by the macro environment but remains confident in the company's ability to adapt and grow [24][25] Other Important Information - The company authorized a $125 million share repurchase program, reflecting confidence in long-term prospects [5][23] - The effective tax rate for the quarter was 29.4%, significantly impacted by the depreciation of the Argentine peso [21][22] Q&A Session Summary Question: Are clients looking for AI use cases in retailing or banking? - Management noted that consumer experience is being transformed with many active projects focusing on conversational interfaces across various industries [28][30] Question: Will AI projects move into mainstream production? - Management indicated that there is a clear evolution from exploratory projects to transformational efforts, with many clients now integrating AI into their core operations [33][34] Question: What is the outlook for headcount and growth in 2026? - Management stated that a combination of higher utilization and new hires will be necessary to support growth, with optimism for better numbers in professional services [78][79] Question: How is the pricing environment affected by GenAI? - Management does not foresee major pricing pressure, emphasizing the value added in their offerings and maintaining revenue per head [48][49] Question: What factors could raise conversion rates for the pipeline? - Management highlighted that improving global economic conditions and a deeper understanding of AI benefits will help accelerate conversion rates [88][90]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 totaled $30.5 million, representing a 2.9% decrease from $31.4 million in Q3 2024 [9] - Gross profit for Q3 2025 was $5 million, or 16.5% of net sales, compared to $3.8 million, or 12.2% of net sales in the same prior year quarter [10][11] - Adjusted EBITDA for Q3 2025 was $1.3 million, significantly up from $143,000 in Q3 2024, reflecting improved efficiencies and productivity [17] Business Line Data and Key Metrics Changes - Aerospace and defense net sales decreased by $1.4 million due to increased production in the latter half of 2024 and delays in product approvals [9] - Medical imaging net sales increased by 8.7% or $832,000 compared to the same quarter in 2024, driven by the transfer of customer programs [10] Market Data and Key Metrics Changes - Customer backlog was $77.3 million as of September 30, 2025, consistent with the backlog at June 30, 2025 [10] - The company is well-positioned in North America, particularly with its Monterrey operations under the USMCA framework, reducing exposure to tariffs [4] Company Strategy and Development Direction - The company is focused on strengthening its balance sheet and reducing inventory investments in 2025 [19] - Investments in regulatory capabilities have been made to leverage future growth, including achieving AS 9100D and CMMC 2.0 certifications [5][19] - The strategic plan emphasizes engineering expertise, product innovation, and sustainability, particularly in fiber optic technology [20][23] Management Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about positioning in the nearshoring landscape and the potential for continued sales momentum in 2025 and beyond [26] - The company believes it has overcome revenue and earning headwinds from changes in customer ordering patterns and delays in aerospace and defense programs [18] Other Important Information - The company incurred a net loss of $146,000 in Q3 2025 due to increased income tax expenses [12] - Cash flow increased to $1.3 million as of September 30, 2025, up from $916,000 at the end of 2024 [15] Q&A Session Summary - There were no questions from the line during the Q&A session [27]

Financial Data and Key Metrics Changes - First fiscal quarter revenue increased by 10% from $5.4 million to $6 million [4] - Income from operations rose by 28% to $1.9 million compared to $1.5 million [5] - GAAP net income increased by 13% to $1.8 million from $1.6 million [6][7] - Earnings per share for the quarter was $0.10 basic and $0.09 diluted, reflecting a year-over-year EPS growth of 13% [8] - Cash from operations decreased to $1.5 million from $1.9 million in the year-ago quarter [8] - Total cash increased to $28.8 million from $28.6 million, maintaining zero bank debt [8] Business Line Data and Key Metrics Changes - All lines of business are experiencing growth, with traditional sales and cross-selling initiatives contributing to accelerated momentum [9] - Revenue per employee is $356,000 annually, significantly higher than the industry average of $175,000 [5] Market Data and Key Metrics Changes - The company is positioned as a dominant player in the traceability and food safety sectors, leveraging its capabilities to grow across all business lines [15][22] - The traceability revenue continues to grow, enhancing the company's reputation in the industry [22] Company Strategy and Development Direction - The company aims to grow annual recurring revenue between 10%-20% and increase profitability at a faster rate [4] - A multi-year initiative to modernize the software code is underway, focusing on automation and AI to enhance operational efficiency [12][20] - The capital allocation strategy includes returning 50% of annual free cash flow to shareholders while maintaining a strong cash reserve [9][10] Management's Comments on Operating Environment and Future Outlook - The management acknowledges a cautious industry environment due to factors like government shutdowns and inflation, but the impact is not substantial [28] - The focus on data integrity and error correction in traceability is seen as a significant opportunity for future growth [30] Other Important Information - The company has redeemed approximately 572,000 shares of preferred stock and continues to repurchase common shares without incurring debt [10][11] - The modernization project is expected to drive significant efficiencies and create incremental value for customers and shareholders [22] Q&A Session Summary Question: How, if at all, were you impacted by the government shutdown? - The shutdown impacts the food industry due to the FDA not working, causing caution in the industry, but the impact is not substantial [28] Question: Do you still believe your by-ingredient efforts are increasing your total addressable market? - Yes, it expands the market as traceability records require participation from suppliers, creating a connected chain [29][32]